Company Overview of Syntaxin Ltd
Syntaxin Ltd., a biotechnology company, discovers and develops biopharmaceuticals that treat diseases through selective inhibition of cell secretory pathways. The company specializes in the design, recombinant expression, and purification of botulinum neurotoxins and targeted secretion inhibitors (TSIs). It develops TSIs for the treatment of a range of diseases, including endocrine, sensory and respiratory conditions, and oncology. The company was founded in 2005 and is based in Oxon, United Kingdom with an office facility in Abingdon, United Kingdom. As of July 15, 2013, Syntaxin Ltd. operates as a subsidiary of Ipsen S.A.
Units 4-10The Quadrant
Oxon, OX14 3YS
Founded in 2005
44 1235 552 100
44 1235 552 200
Key Executives for Syntaxin Ltd
Syntaxin Ltd Key Developments
Similar Private Companies By Industry
|Oxford Cancer Biomarkers Ltd||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Syntaxin Ltd, please visit www.syntaxin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.